Beneficial ownership — 13D / 13G
87,387 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.
Coverage begins December 2024, when the SEC required these schedules to be filed as structured XML.
| Reporting person | Issuer | Schedule | % of class | Event date | Filed |
|---|---|---|---|---|---|
| Global X Management CO LLC | CMCO Columbus Mckinnon Corp | 13G | 6.15% | Mar 31, 2026 | 6mo |
| Lagoda Investment Management, L.P. | STXS Stereotaxis, Inc. | 13G/A | 4.5% | Mar 31, 2026 | 6mo |
| MORGAN STANLEY | XIFR XPLR Infrastructure, LP | 13G | 7.1% | Mar 31, 2026 | 6mo |
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | NOV NOV Inc. | 13G/A | 4.14% | Mar 31, 2026 | 6mo |
| T. Rowe Price Investment Management, Inc. | AEE Ameren Corp | 13G/A | 2.7% | Mar 31, 2026 | 6mo |
| METEORA CAPITAL, LLC | APXT Apex Treasury Corp | 13G/A | 7.8% | Mar 31, 2026 | 6mo |
| Pentwater Capital Management LP | AMC Amc Entertainment Holdings, Inc. | 13G | 9.99% | Mar 31, 2026 | 6mo |
| ARMISTICE CAPITAL, LLC | AGIO Agios Pharmaceuticals, Inc. | 13G/A | 4.57% | Mar 31, 2026 | 6mo |
| PRICE T ROWE ASSOCIATES INC /MD/ | CCC CCC Intelligent Solutions Holdings Inc. | 13G | 5.5% | Mar 31, 2026 | 6mo |
| METEORA CAPITAL, LLC | RAIN Rain Enhancement Technologies Holdco, Inc. | 13G | 7.85% | Mar 31, 2026 | 6mo |
| ORBIMED ADVISORS LLC | NPCE NeuroPace Inc | 13G/A | 6.2% | Mar 31, 2026 | 6mo |
| CITY OF LONDON INVESTMENT MANAGEMENT CO LTD | IIF Morgan Stanley India Investment Fund, Inc. | 13G/A | 10.1% | Mar 31, 2026 | 6mo |
| Tangney Jeffrey | DOCS Doximity, Inc. | 13G/A | 29.9% | Mar 31, 2026 | 6mo |
| Seven Fleet Capital Management LP | CTMX CytomX Therapeutics, Inc. | 13G/A | 0.5% | Mar 31, 2026 | 6mo |
| Berkshire Hathaway Inc | DPZ Dominos Pizza Inc | 13G/A | 0% | Mar 31, 2026 | 6mo |
| MSOP GP, L.L.C. | CHYM Chime Financial, Inc. | 13G/A | 2.8% | Mar 31, 2026 | 6mo |
| Alyeska Investment Group, L.P. | MTVA MetaVia Inc. | 13G | 9.99% | Mar 31, 2026 | 6mo |
| RIVERNORTH CAPITAL MANAGEMENT, LLC | GLO Clough Global Opportunities Fund | 13G/A | 5.22% | Mar 31, 2026 | 6mo |
| Bentley Corinne Patricia | BSY Bentley Systems Inc | 13G/A | 13.2% | Mar 31, 2026 | 6mo |
| Extract Advisors LLC | AEC Anfield Energy Inc. | 13G/A | 6.6% | Mar 31, 2026 | 6mo |
| BIOTECHNOLOGY VALUE FUND L P | CGEM Cullinan Therapeutics, Inc. | 13G/A | 9.99% | Mar 31, 2026 | 6mo |
| DARLINGTON PARTNERS CAPITAL MANAGEMENT, LP | FOUR Shift4 Payments, Inc. | 13G/A | 8.3% | Mar 31, 2026 | 6mo |
| GREAT POINT PARTNERS LLC | CNTX Context Therapeutics Inc. | 13G/A | 2.44% | Mar 31, 2026 | 6mo |
| Commodore Capital LP | ANRO Alto Neuroscience, Inc. | 13G/A | 9.9% | Mar 31, 2026 | 6mo |
| Wesley Mendonca Batista | PICS PicS N.V. | 13G | 74.5% | Mar 31, 2026 | 6mo |
| Hood River Capital Management LLC | HCI HCI Group, Inc. | 13G/A | 4.8% | Mar 31, 2026 | 6mo |
| Alyeska Investment Group, L.P. | MRLN Merlin, Inc. | 13G | 9.9% | Mar 31, 2026 | 6mo |
| Northern Right Capital Management, L.P. | GECC Great Elm Capital Corp. | 13G/A | 3.3% | Mar 31, 2026 | 6mo |
| AQR CAPITAL MANAGEMENT LLC | BFAM Bright Horizons Family Solutions Inc. | 13G | 6.04% | Mar 31, 2026 | 6mo |
| TCG Crossover GP II, LLC | TNGX Tango Therapeutics, Inc. | 13G/A | 8.1% | Mar 31, 2026 | 6mo |
| LAZARD ASSET MANAGEMENT LLC | MXF Mexico Fund Inc | 13G | 5% | Mar 31, 2026 | 6mo |
| EcoR1 Capital, LLC | XNCR Xencor Inc | 13G/A | 2.9% | Mar 31, 2026 | 6mo |
| TANG CAPITAL MANAGEMENT LLC | CBIO Crescent Biopharma, Inc. | 13G/A | 4.21% | Mar 31, 2026 | 6mo |
| WELLINGTON MANAGEMENT GROUP LLP | PEBK Peoples Bancorp Of North Carolina Inc | 13G/A | 7.7% | Mar 31, 2026 | 6mo |
| Fort Baker Capital Management LP | PMTR Perimeter Acquisition Corp. I | 13G | 6.3% | Mar 31, 2026 | 6mo |
| Nantahala Capital Management, LLC | GOGO Gogo Inc. | 13G/A | 6.59% | Mar 31, 2026 | 6mo |
| PLATINUM EQUITY, LLC | INGM Ingram Micro Holding Corp | 13G/A | 85.1% | Mar 31, 2026 | 6mo |
| VIKING GLOBAL INVESTORS LP | LAB Standard Biotools Inc. | 13G/A | 15% | Mar 31, 2026 | 6mo |
| Alyeska Investment Group, L.P. | CRML Critical Metals Corp. | 13G/A | 8.07% | Mar 31, 2026 | 6mo |
| RTW INVESTMENTS, LP | CADL Candel Therapeutics, Inc. | 13G | 8.8% | Mar 31, 2026 | 6mo |
| Newtyn Management, LLC | PAR Par Technology Corp | 13G | 6.6% | Mar 31, 2026 | 6mo |
| ATW Growth Opportunities SPV, LLC | WKHS Workhorse Group Inc. | 13G/A | 5% | Mar 31, 2026 | 6mo |
| ARMISTICE CAPITAL, LLC | ESLA Estrella Immunopharma, Inc. | 13G | 9.99% | Mar 31, 2026 | 6mo |
| ARMISTICE CAPITAL, LLC | CTOR Citius Oncology, Inc. | 13G/A | 9.99% | Mar 31, 2026 | 6mo |
| WELLINGTON MANAGEMENT GROUP LLP | MEOH Methanex Corp | 13G | 5.8% | Mar 31, 2026 | 6mo |
| Caracola Ventures Corp | NUAI New ERA Energy & Digital, Inc. | 13G/A | 8.6% | Mar 31, 2026 | 6mo |
| MMCAP International Inc. SPC | WSTRF Western Uranium & Vanadium Corp. | 13G/A | 5% | Mar 31, 2026 | 6mo |
| CITY OF LONDON INVESTMENT MANAGEMENT CO LTD | EMF Templeton Emerging Markets Fund | 13G/A | 23.7% | Mar 31, 2026 | 6mo |
| Logos Global Management LP | AVTX Avalo Therapeutics, Inc. | 13G/A | 3.2% | Mar 31, 2026 | 6mo |
| T. Rowe Price Investment Management, Inc. | STVN Stevanato Group S.p.A. | 13G/A | 6.5% | Mar 31, 2026 | 6mo |